Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

Trevi Therapeutics (NASDAQ:TRVI) PT Raised to $12.00

kopsource ·  {{timeTz}}

Trevi Therapeutics (NASDAQ:TRVI – Get Rating) had its price target raised by Oppenheimer to $12.00 in a research report sent to investors on Monday, Stock Target Advisor reports.

Several other brokerages have also recently weighed in on TRVI. Aegis assumed coverage on Trevi Therapeutics in a research note on Tuesday, March 29th. They set a buy rating and a $10.00 price objective on the stock. Needham & Company LLC raised their price objective on Trevi Therapeutics from $8.00 to $10.00 and gave the company a buy rating in a research note on Wednesday, June 29th.

Get Trevi Therapeutics alerts:

Shares of TRVI opened at $3.79 on Monday. Trevi Therapeutics has a 12-month low of $0.46 and a 12-month high of $3.86. The business's fifty day moving average is $2.40 and its 200 day moving average is $1.74. The company has a quick ratio of 2.32, a current ratio of 2.32 and a debt-to-equity ratio of 0.67. The stock has a market cap of $146.64 million, a P/E ratio of -2.81 and a beta of 0.18.

Trevi Therapeutics (NASDAQ:TRVI – Get Rating) last issued its earnings results on Thursday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.07. During the same period in the prior year, the firm earned ($0.43) earnings per share. On average, analysts expect that Trevi Therapeutics will post -0.81 EPS for the current year.

In other news, major shareholder Paul Edward Walker acquired 3,580,526 shares of the firm's stock in a transaction that occurred on Monday, April 11th. The stock was bought at an average price of $1.90 per share, with a total value of $6,802,999.40. Following the acquisition, the insider now owns 10,421,428 shares in the company, valued at approximately $19,800,713.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Tpg Gp A, Llc sold 436,431 shares of Trevi Therapeutics stock in a transaction dated Friday, July 1st. The shares were sold at an average price of $2.86, for a total value of $1,248,192.66. Following the transaction, the insider now directly owns 3,888,452 shares of the company's stock, valued at approximately $11,120,972.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 553,999 shares of company stock valued at $1,594,044. Insiders own 47.30% of the company's stock.

A number of hedge funds have recently bought and sold shares of TRVI. Commonwealth Equity Services LLC purchased a new position in Trevi Therapeutics during the 1st quarter valued at about $33,000. WealthTrust Axiom LLC boosted its position in shares of Trevi Therapeutics by 245.6% during the 1st quarter. WealthTrust Axiom LLC now owns 98,500 shares of the company's stock valued at $216,000 after acquiring an additional 70,000 shares during the last quarter. MAI Capital Management bought a new stake in shares of Trevi Therapeutics during the 1st quarter valued at about $3,391,000. Vanguard Group Inc. boosted its position in shares of Trevi Therapeutics by 7.6% during the 1st quarter. Vanguard Group Inc. now owns 152,831 shares of the company's stock valued at $336,000 after acquiring an additional 10,780 shares during the last quarter. Finally, State Street Corp bought a new stake in shares of Trevi Therapeutics during the 1st quarter valued at about $81,000. 75.34% of the stock is owned by institutional investors and hedge funds.

About Trevi Therapeutics (Get Rating)

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis.

Featured Articles

  • Get a free copy of the StockNews.com research report on Trevi Therapeutics (TRVI)
  • 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
  • Credo Technology Stock is Rebounding
  • Investing In Preferred Stock vs. Common Stock
  • Profiting From 52 Week Low Stocks
  • Three Cheap Stocks The Insiders Are Buying

Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top